Overview

A Study of Hydroxychloroquine Sulfate in the Treatment of Recurrent Spontaneous Abortion With Antiphospholipid Syndrome

Status:
Not yet recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

The efficacy of low-dose aspirin combined with low-molecular-weight heparin treatment for improving antiphospholipid syndrome and maternal-fetal outcome of patients is recognized by various countries and recommended by the guidelines. However, there are still 20-30% of APS patients whose treatment fails. Therefore, the standard treatment effect is still not ideal, and other treatment options need to be explored. The purpose of this study is to conduct a randomized double-blind, parallel controlled study of patients with recurrent miscarriage and APS in addition to standard treatment, plus hydroxychloroquine sulfate (HCQ) or placebo, to observe the effects of HCQ on pregnancy outcome in patients with abortion and APS, to evaluate the effectiveness and safety of HCQ treatment.

Phase:

Phase 4

Details

Lead Sponsor:

Shanghai First Maternity and Infant Hospital

Collaborators:

Fudan University
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Zhejiang Provincial People's Hospital
Zhejiang Provincial Tongde Hospital

Treatments:

Hydroxychloroquine